Abstracts tagged "infection and rheumatoid arthritis (RA)"

Abstract Number: 2452 • 2018 ACR/ARHP Annual Meeting
Incidence Rate and Clinical Characteristics of Herpes Zoster Infection in Korean Patients with Rheumatoid Arthritis Patients
Su-Jin Moon¹, Min Jung Kim², Sun Kyung Lee², So Hee Oh², Hyoun-Ah Kim³ and Kichul Shin⁴, ¹Bucheon St. Mary's Hospital, Division of rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Bucheon, Korea, Republic of (South), ²Division of Rheumatology, Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of (South), ³Department of Rheumatology, Ajou University School of Medicine, Suwon, Korea, Republic of (South), ⁴Kyungnam villa #102, Division of Rheumatology, Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of (South)
Background/Purpose: Herpes zoster (HZ) infection is not uncommon in rheumatoid arthritis (RA) patients, especially in those treated with biologic or targeted synthetic (bts) disease-modifying antirheumatic…
Abstract Number: 2485 • 2018 ACR/ARHP Annual Meeting
Comparison of Risk for Infection-Related Hospitalization and Associated Costs of Biologic Experienced Rheumatoid Arthritis Patients Treated with Abatacept Versus Other Targeted Disease Modifying Antirheumatic Drugs
Damemarie Paul¹, Laura McDonald¹, Alexander Marshall², Tammy Curtice³, Melissa Lingohr-Smith⁴, Brandy Menges⁴ and Jay Lin⁴, ¹Bristol-Myers Squibb, Lawrenceville, NJ, ²HEOR, Bristol-Myers Squibb, Lawrenceville, NJ, ³Bristol-Myers Squibb, Princeton, NJ, ⁴Novosys Health, Green Brook, NJ
Background/Purpose: Abatacept is a targeted disease-modifying antirheumatic drug (tDMARD) that has demonstrated a lower risk for infection in comparison with other tDMARDs among rheumatoid arthritis…
Abstract Number: 223 • 2018 ACR/ARHP Annual Meeting
The Effect of Concomitant Diabetes on RA-Related Outcomes: Results from the Acr’s RISE Registry
Huifeng Yun¹, Fenglong Xie¹, Lang Chen¹, Shuo Yang¹, Leticia Ferri², Evo Alemao², Tammy Curtice² and Jeffrey R. Curtis¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: The impact of concomitant comorbidities on RA outcomes is of high interest, and some evidence suggests that patients (pts) with RA and diabetes may…
Abstract Number: 519 • 2018 ACR/ARHP Annual Meeting
Marginal Structure Modeling of Association between Disease Activity and Hospitalized Infection Among Patients in a Rheumatoid Arthritis Registry
Huifeng Yun¹, Lang Chen¹, Jason Roy², Jeffrey D. Greenberg³ and Jeffrey R. Curtis¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Pennsylvania, Philadelphia, PA, ³Hopital Hautepierre, Strasbourg, France
Background/Purpose: Higher disease activity might be associated with a higher risk of developing infections among patients with rheumatoid arthritis (RA). Since no randomized trial has…
Abstract Number: 526 • 2018 ACR/ARHP Annual Meeting
Bronchiectasis in RA Is a Crucial Risk Factor of Hospitalised Pneumonia Associated with Bdmards As Well As Interstitial Lung Disease
Kyoko Honne¹, Masashi Bando², Makiko Mieno³, Masahiro Iwamoto⁴ and Seiji Minota⁵, ¹Division of Rheumatology and Clinical Immunology, Jichi Medical University, Shimotsuke, Japan, ²division of pulmonary medicine, Department of medicine, Jichi Medical University, Shimotsuke, Japan, ³Center for Information, Jichi Medical University, Shimotsuke, Japan, ⁴Deivision of Rheumatology and Clinical Immunology, Jichi Medical University, Shimotsuke, Japan, ⁵Department of Internal Medicine, Division of Rheumatology/Clinical Immunology, Jichi Medical University, Shimotsuke, Japan
Background/Purpose: Interstitial lung disease (ILD) is a risk factor of pneumonia in RA patients treated with biological DMARDs (bDMARDs) [1-4]. Bronchiectasis (BE) is a well-known…
Abstract Number: 1226 • 2018 ACR/ARHP Annual Meeting
Effect of New Method for Pre-Administration Assessment of Intravenous Biologics on Infections in Patients with Rheumatoid Arthritis
Sho Fukui¹, Masei Suda², Haruki Sawada³, Yukihiko Ikeda¹, Mitsuru Watanabe⁴, Ayako Koido⁴, Rui Kawato⁵, Yasuhiro Suyama⁶, Hisanori Shimizu⁷, Haruyuki Yanaoka⁷, Ryo Rokutanda¹, Hiromichi Tamaki¹, Tokutaro Tsuda¹, Ken-ichi Yamaguchi⁸, Mitsumasa Kishimoto¹ and Masato Okada⁹, ¹Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, ²Immuno-Rheumatology Center, St luke's International hospital, Tokyo, Japan, ³Immuno-rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, ⁴Immune-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan, ⁵Immuno rheumatology center, St. Luke's International Hospital, Tokyo, Japan, ⁶Division of Rheumatology, JR Tokyo General Hospital, Tokyo, Japan, ⁷St. Luke's International Hospital, Tokyo, Japan, ⁸Allergy and Rheumatology, St. Luke's International Hospital, Tokyo, Japan, ⁹Immuno-Rheumatology Center, St. Luke’s International Hospital, Tokyo, Japan
Background/Purpose: Biologics are widely used and effective treatments for rheumatoid arthritis (RA), but generally biologics are avoided when patients have active infections on the day…
Abstract Number: 2449 • 2018 ACR/ARHP Annual Meeting
Prevalence and Risk Factors of Serious Infections in Rheumatoid Arthritis Patients Receiving the Biologic/Targeted Synthetic Dmards: A Propensity Score Analysis from the Hong Kong Biologics Registry
Chi Chiu Mok, Ting Hung Wan and Lai Shan Fong, Medicine, Tuen Mun Hospital, Hong Kong, Hong Kong
Background/Purpose: To study the prevalence and risk factors for serious infections (SIs) in rheumatoid arthritis (RA) patients receiving the biologic / target synthetic (b/ts) DMARDs.…
Abstract Number: 134 • 2017 ACR/ARHP Annual Meeting
Baseline Characteristics and Rates of Hospitalized Infections in Patients with Rheumatoid Arthritis Treated with Non-TNF Inhibitors in Denmark and Sweden
Kathrine Lederballe Grøn¹, Elizabeth V. Arkema², Bente Glintborg¹, Johan Askling³ and Merete Lund Hetland⁴, ¹The DANBIO registry and the Danish Departments of Rheumatology, Copenhagen, Denmark, ²Clinical Epidemiology Unit, Department of Medicine, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, ³Unit of Clinical Epidemiology, Department of Medicine, Karolinska University Hospital and Karolinska Institutet, Stockholm, Sweden, ⁴The DANBIO registry and the Danish Departments of Rheumatology, Glostrup, Denmark
Background/Purpose: Hospitalized infections during treatment with biologic disease modifying drugs (bDMARDs) in rheumatoid arthritis (RA) are a concern. This have mainly been studied in patients…
Abstract Number: 528 • 2017 ACR/ARHP Annual Meeting
Impact of Comorbidities on the Occurrence of Infections in Rheumatoid Arthritis Treated By Biologic Agents
Christopher Banse¹, Nicolas Chrin², Pascal Rottenberg³, Sophie Pouplin⁴, thierry Lequerre⁵ and Olivier Vittecoq³, ¹Rheumatology, Rouen University Hospital, Rouen, France, ²Department of Biostatistics, Rouen University Hospital, 76031 Rouen, France, ROUEN, France, ³INSERM U905 & Normandy University, Institute for Research and Innovation in Biomedicine, Rouen, France, ⁴Rheumatology Department & Inserm 905, Department of Rheumatology, Rouen University Hospital & Inserm 905, Institute for Biomedical Research, University of Rouen, Rouen, France, ⁵Rheumatology Department, Rouen University Hospital, University of Rouen, 76031 Rouen, France., ROUEN, France
Background/Purpose: to investigate the potential relationship between the number of comorbidities at initiation of biotherapy and the occurrence of a severe infection or recurrent infections…
Abstract Number: 813 • 2017 ACR/ARHP Annual Meeting
Incidence of Herpes Zoster in Patients with Polymyalgia Rheumatica: A Population-Based Cohort Study
Shafay Raheel¹, Cynthia S. Crowson² and Eric L. Matteson³, ¹Rheumatology, Mayo Clinic, Rochester, MN, ²Health Sciences Research, Mayo Clinic College of Medicine and Science, Rochester, MN, ³Rheumatology, Mayo Clinic College of Medicine and Science, Rochester, MN
Background/Purpose: To determine the incidence, time trends and, severity of herpes zoster in a population-based incidence cohort of patients with polymyalgia rheumatic (PMR) compared to…
Abstract Number: 842 • 2017 ACR/ARHP Annual Meeting
Risk of Serious Infection in Patients with Rheumatoid Arthritis Treated with Biologic Vs. Non-Biologic Dmards
Gulsen Ozen¹, Sofia Pedro², Bryant R. England³, Bella Mehta⁴, Frederick Wolfe² and Kaleb Michaud¹, ¹Rheumatology, University of Nebraska Medical Center, Omaha, NE, ²National Data Bank for Rheumatic Diseases, Wichita, KS, ³Division of Rheumatology & Immunology, Department of Internal Medicine, Nebraska-Western IA VA Health Care System & University of Nebraska Medical Center, Omaha, NE, ⁴Rheumatology, Hospital for Special Surgery/Weill Cornell Medical College, New York, NY
Background/Purpose: Serious infections (SIs) are a major concern in RA patients, significantly contributing to increased mortality. We examined the SI risk associated with bDMARDs compared…
Abstract Number: 2391 • 2017 ACR/ARHP Annual Meeting
Incidence of Infections in Early Arthritis
Meriem Kerbachi¹, Louis Bessette², Cristiano S. Moura³, Sasha Bernatsky⁴, Orit Schieir⁵, Susan J. Bartlett⁶, Carol A Hitchon⁷, Janet E. Pope⁸, Gilles Boire⁹, Boulos Haraoui¹⁰, Edward C. Keystone¹¹, Diane Tin¹², Carter Thorne¹³ and Vivian P. Bykerk¹⁴, ¹McGill University, Montreal, QC, Canada, ²Centre d'ostéoporose et de rhumatologie de Québec (CORQ), Québec, QC, Canada, ³1Division of Clinical Epidemiology, McGill University Health Centre, Montreal, QC, Canada, ⁴Divisions of Rheumatology and Clinical Epidemiology, Research Institute of the McGill University Health Centre, Montreal, QC, Canada, ⁵McGill University, Montreal, ON, Canada, ⁶Department of Medicine, Division of ClinEpi, Rheumatology, Respirology, McGill University, Montreal, QC, Canada, ⁷University of Manitoba, Winnipeg, MB, Canada, ⁸Department of Medicine, Division of Rheumatology, University of Western Ontario, St Joseph's Health Care, London, ON, Canada, ⁹Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke and Universite de Sherbrooke, Sherbrooke, QC, Canada, ¹⁰Institut de Rhumatologie de Montréal, Montreal, QC, Canada, ¹¹Mt. Sinai Hospital, University of Toronto, Toronto, ON, Canada, ¹²The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ¹³University of Toronto, Newmarket, ON, Canada, ¹⁴2-005, Mt Sinai Hospital, Toronto, ON, Canada
Background/Purpose: Few studies have focused on analyzing infection risk in recent-onset rheumatoid arthritis (RA).The main objective of this study was to estimate the incidence of…
Abstract Number: 471 • 2016 ACR/ARHP Annual Meeting
Epstein-Barr Virus-Induced Expression of Receptor Activator Nuclear Factor-κb Ligand on B Cells Is Possibly Responsible for Erosive Arthritis in Epstein-Barr Virus-Infected Humanized Nonobese Diabetic/Shi-Scid/γcnull Mice
Mitsuhiro Iwata¹, Yosuke Nagasawa¹, Noboru Kitamura¹, Takamasa Nozaki¹, Eiko Ishizuka¹, Ken-Ichi Imadome², Shigeyoshi Fujiwara³ and Masami Takei¹, ¹Division of Hematology and Rheumatology, Nihon University School of Medicine, Tokyo, Japan, ²Division of Advanced Medicine for Virus Infections, National Research Institute for Child Health and Development, Tokyo, Japan, ³Department of Allergy and Clinical Immunology, National Research Institute for Child Health and Development, Tokyo, Japan
Background/Purpose: Humanized nonobese diabetic/Shi-scid/γcnull (NOG) mice, which are reconstituted with human hematoimmune system by transplantation with human CD34＋ hematopoietic stem cells (termed as humanization), have…
Abstract Number: 1496 • 2016 ACR/ARHP Annual Meeting
Risk for Serious Infection in Rheumatoid Arthritis Associated Interstitial Lung Disease
Alex Zamora-Legoff¹, Megan Krause², Cynthia S. Crowson³, Jay H. Ryu⁴ and Eric L. Matteson², ¹Division of Rheumatology, Mayo Clinic, Rochester, MN, ²Rheumatology, Mayo Clinic, Rochester, MN, ³Health Sciences Research, Mayo Clinic, Rochester, MN, ⁴Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN
Background/Purpose: Rheumatoid arthritis (RA) associated interstitial lung disease (ILD) carries a risk for serious infection due to lung disease, immunosuppressive therapy, and RA disease itself.…
Abstract Number: 1504 • 2016 ACR/ARHP Annual Meeting
Fluoroquinolone Resistance in Escherichia coli Urinary Tract Infections Among Patients with Rheumatoid Arthritis: Does Use of Hydroxichloroquine Matter?
Karen Ferez-Blando¹, Hilda Fragoso-Loyo², Alfredo Ponce de León³, Sergio Ponce de Leon-Rosales⁴ and Yemil Atisha-Fregoso¹, ¹Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ²Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ³Department of Infectology and Microbiology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ⁴Direccion de Enseñanza, Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico
Background/Purpose: Rheumatoid arthritis (RA) is a chronic autoimmune disease that requires chronic immunosuppressive treatment. Urinary tract infections (UTI) are common among patients with RA. It…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].